PHK
XENE icon

Point72 Hong Kong’s Xenon Pharmaceuticals XENE Stock Holding History

Point72 Hong Kong’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-329
Closed -$11K – 721
2025
Q1 		$11K Buy
+329
New +$12.5K ﹤0.01% 421

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Point72 Hong Kong's XENE Position: Q2 2025 in Review

Point72 Hong Kong sold out of Xenon Pharmaceuticals (XENE) in Q2 2025, closing a stake of 329 shares — an estimated $11K sold.

Point72 Hong Kong first reported a position in XENE in Q1 2025 and held it in 1 quarter. The position peaked at $11K in Q1 2025. 206 funds tracked by Wall St. Rank hold XENE as of Q2 2025.

  • Point72 Hong Kong reported no remaining Xenon Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Point72 Hong Kong sold 329 Xenon Pharmaceuticals shares in Q2 2025, an estimated $11K.
  • Point72 Hong Kong first reported a position in Xenon Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Point72 Hong Kong's Xenon Pharmaceuticals position peaked at $11K in Q1 2025.
  • 206 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2025.

Based on Point72 Hong Kong's 13F filing for Q2 2025, filed 14 Aug 2025.